Champions Biotechnology signs licensing agreement with Yale University and Southern Research
CSBRE | Quote | Chart | News | PowerRating -- Champions Biotechnology, Inc. (CBI), an oncology drug development company, has signed an exclusive licensing agreement with Yale University and Southern Research Institute for the development of Bithionol for cancer treatment. All the entities are based in the US.
Under the terms of the agreement, CBI will have exclusive rights and be responsible for the further development of Bithionol for all oncology indications. Yale and Southern Research will receive an upfront payment and will be eligible to receive milestone payments and royalties. Additionally, the parties have agreed upon certain terms favorable to developing world markets.
CBI will use its predictive Biomerk TumorgraftT(TM) platform to assess the efficacy of the compound-alone and in combination with other compounds-to determine its optimal application and enable efficient clinical development. Upon successful results, CBI will move the compound forward into human clinical trials.
Deal Type Partnership
Sub-Category Development,Acquisition of Rights
Deal Status Announced: 2009-11-18
Deal Participants
Partner 1 (Company) Southern Research Institute
Partner 2 (Company) Champions Biotechnology, Inc.
Partner 3 (Company) Yale University
For full details on (CSBRE) CSBRE. (CSBRE) has Short Term PowerRatings at TradingMarkets. Details on (CSBRE) Short Term PowerRatings is available at This Link.
- Stockguru.com: Champions Biotechnology Inc. is in the StockGuru Spotlight for December 16, 2009 - 12/16/09
- Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results - 12/15/09
- Champions Biotechnology signs licensing agreement with Yale University and SRI - 11/19/09
- StockProfiler.US: Stock News Update: TDEY, VHGI, CSBR, BVRSF, DGLP, ATTUF - 11/18/09
- CSBR: Licensing Agreement w/Yale University and Southern Research Institute - 11/18/09
- More News >>


